Meeting
2022 ASCO Annual Meeting
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
Authors
Jonathan W. Goldman
David Geffen School of Medicine at UCLA, Los Angeles, CA
Jonathan W. Goldman , Hidehito Horinouchi , Byoung Chul Cho , Pascale Tomasini , Martin Dunbar , David Hoffman , Apurvasena Parikh , Vincent Blot , D. Ross Camidge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02099058
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9013)
DOI
10.1200/JCO.2022.40.16_suppl.9013
Abstract #
9013
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.
First Author: Rebecca Suk Heist
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2024 ASCO Annual Meeting
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: Shen Zhao
Poster
2023 ASCO Annual Meeting
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
First Author: Fengying Wu